Loading...
•
Jun 30, 2023
Praxis Q2 2023 Earnings Report
Praxis Precision Medicines reported financial results for the second quarter 2023.
Key Takeaways
Praxis Precision Medicines reported a net loss of $34.3 million for the second quarter of 2023. The company's cash and cash equivalents were $124.3 million as of June 30, 2023, expected to support runway into Q1 2025.
On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA.
PRAX-628 Phase 1 study showed consistent safety profile and target engagement in measures of qEEG activity at all doses with first administration.
Praxis will hold an R&D Portfolio Day on October 2.
Cash of $124.3 million as of June 30, 2023 expected to support runway into Q1 2025.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...